Coreo AG — Capital/Financing Update 2010

Jun 16, 2010

News Details

Corporate | 16 June 2010 21:14

Nanostart subsidiary MagForce Nanotechnologies AG announces capital increase with exclusion of subscription rights

Nanostart AG / Miscellaneous

16.06.2010 21:14

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Frankfurt / Berlin - June 16, 2010 - Nanostart subsidiary MagForce
Nanotechnologies AG, a medical technology company listed in the Entry
Standard segment of the Frankfurt Stock Exchange, today announced its
intention to increase its share capital under the procedure to exclude
subscription rights for existing investors. The company's nominal capital
is EUR 3,773,198.00, divided into 3,773,198 common shares in bearer form
with an imputed nominal value of EUR 1.00. In its resolution of the June
16, 2010, approved by the supervisory board on June 16, 2010, the executive
board of MagForce Nanotechnologies has decided to increase its share
capital by up to EUR 80,190 against cash contributions, bringing its
approved capital limit up to EUR 3,853,388.

Up to 80,190 new common shares will be issued, with profit participation
rights dating from January 1, 2009. The company has excluded subscription
rights to existing shareholders by its authority under sec. 6 para. 3 of
its articles of incorporation (Satzung). The new shares will be privately
placed with German and international institutional investors at an offering
price of EUR 42.00 per share.

The proceeds of the capital increase are to be used to finance the
company's further growth.

About Nanostart:
Nanostart AG is the world's leading nanotechnology investment company. The
Frankfurt-based company provides venture capital financing for
nanotechnology companies in various growth phases. It also provides the
benefits of its experience and expertise to developers of financial
instruments and to investors in the nanotechnology sector. For further
information about the company, please visit www.nanostart.de.

About MagForce Nanotechnologies:

MagForce Nanotechnologies AG is a world-leading company in the area of
nanotechnology-based cancer treatment. Its patented Nano-Cancer(R) therapy
enables the targeted destruction of tumors using superparamagnetic
nanoparticles to generate heat. The nanotechnology from MagForce represents
a revolutionary approach to the future successful treatment of solid
tumors.

Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within the United States of America, Canada, Australia or
Japan.

Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse@nanostart.de

16.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---